Timothy Eugene Sullivan - 20 Jan 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/ David Watson, attorney-in-fact for Timothy Sullivan
Issuer symbol
APLS
Transactions as of
20 Jan 2026
Net transactions value
-$57,241
Form type
4
Filing time
21 Jan 2026, 16:10:29 UTC
Previous filing
15 Jan 2026
Next filing
23 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sullivan Timothy Eugene Chief Financial Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Timothy Sullivan 21 Jan 2026 0001707000

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $57,241 -2,892 -2.7% $19.79 104,188 20 Jan 2026 Direct F1
holding APLS Common Stock 60,396 20 Jan 2026 The Timothy E Sullivan Irrevocable Trust of 2023 F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026.
F2 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.